Richard M. Ferrari Net Worth

The estimated Net Worth of Richard Ferrari is at least $67.6 Thousand dollars as of 8 November 2022. Mr Ferrari owns over 5,438 units of HeartBeam Inc stock worth over $67,579 and over the last 4 years he sold BEAT stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Ferrari BEAT stock SEC Form 4 insiders trading

Mr has made over 3 trades of the HeartBeam Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 5,438 units of BEAT stock worth $28,876 on 8 November 2022.

The largest trade he's ever made was exercising 65,653 units of HeartBeam Inc stock on 11 November 2021 worth over $275,743. On average, Mr trades about 7,659 units every 69 days since 2020. As of 8 November 2022 he still owns at least 30,035 units of HeartBeam Inc stock.

You can see the complete history of Mr Ferrari stock trades at the bottom of the page.

Mr. Richard M. Ferrari biography

Richard M. Ferrari is the Exec. Chairman at HeartBeam Inc.

How old is Mr Ferrari?

Mr Ferrari is 67, he's been the Exec. Chairman of HeartBeam Inc since . There are 5 older and 11 younger executives at HeartBeam Inc. The oldest executive at HeartBeam Inc is Robert Rubin, 74, who is the Independent Director.

What's Mr Ferrari's mailing address?

Richard's mailing address filed with the SEC is 2118 WALSH AVE, SUITE 210, , SANTA CLARA, CA, 95050.

Insiders trading at HeartBeam Inc

Over the last 11 years, insiders at HeartBeam Inc have traded over $23,124,978 worth of HeartBeam Inc stock and bought 31,500 units worth $221,145 . The most active insiders traders include Joseph H Capper, Heather C Getz, and Willem Elfrink. On average, HeartBeam Inc executives and independent directors trade stock every 32 days with the average trade being worth of $55,046. The most recent stock trade was executed by Urioste George De on 6 September 2024, trading 1,674 units of BEAT stock currently worth $3,917.

What does HeartBeam Inc do?

heartbeam developed a mhealth technology that is diagnostically equivalent to a cardiologist reading a patient’s 12 lead ecg and examining the patient. it comprises a credit card size, 12 lead equivalent, ecg device and a cloud-based diagnostic expert system. studies designed by harvard medical school faculty have shown heartbeam performance to be equal or better than world class cardiologists in diagnosing a heart attack. the technology features personalized diagnostic thresholds and novel heart attack ecg markers from which the application can also help cardiologists locate a heart attack on a 3d model of the heart. heartbeam's icardiologist application utilizes artificial intelligence / machine learning to drive continuous improvements of the system's ability to provide patient analysis and improve the solution's predictive properties.

Complete history of Mr Ferrari stock trades at HeartBeam Inc and Pulmonx Corp

HeartBeam Inc executives and stock owners

HeartBeam Inc executives and other stock owners filed with the SEC include:

• Joseph Capper,
  President, Chief Executive Officer, Director
• Heather Getz,
  Chief Financial Officer, Executive Vice President, Chief Administrative Officer
• Fred Broadway,
  President, BioTel Heart
• Daniel Wisniewski,
  Senior Vice President - Technical Operations
• Kirk Gorman,
  Independent Chairman of the Board
• Rebecca Rimel,
  Independent Director
• Anthony Conti,
  Independent Director
• Joseph Frick,
  Independent Director
• Stephan Rietiker,
  Director
• Robert Rubin,
  Independent Director
• Colin Hill,
  Independent Director
• Tiffany Olson,
  Independent Director
• Laura Dietch,
  Independent Director
• Dr. Branislav Vajdic Ph.D.,
  Founder, CEO & Director
• Richard D. Brounstein,
  Chief Financial Officer
• Manish Wadhwa,
  Chief Medical Officer
• Andrei Stoica,
  Chief Technology Officer
• Dr. Peter J. Fitzgerald FACC, M.D., Ph.D.,
  Chief Medical Officer
• Ken Persen,
  Chief Technology Officer
• Dr. Jon Hunt Ph.D.,
  Exec. VP & Chief Bus. Officer
• Alexei Shvilkin M.D.,
  Chief Medical Officer
• Dr. Dorin Panescu Ph.D.,
  Chief Technical Officer
• Alan Baumel,
  Chief Operating Officer
• Richard M. Ferrari,
  Exec. Chairman
• George Hrenko,
  Senior Vice President
• Stephen Rietiker,
  Director
• Michael Geldart,
  Senior Vice President
• Ronald A Ahrens,
  Director
• Eric N Prystowsky,
  Director
• Peter Ferola,
  SVP & General Counsel
• Kenneth Warwick Iii Nelson,
  Director
• Mark E Strome,
  10% owner
• Michael R Jaff,
  Director
• Willem Elfrink,
  Director
• Marga Ortigas Wedekind,
  Director
• Urioste George De,
  Director
• Richard Ferrari,
  Director
• Jon Patrick Hunt,
  Chief Business Officer
• Richard Brounstein,
  Chief Financial Officer
• Alan Baumel,
  Chief Operating Officer
• Kenneth Harry Persen,
  Chief Technology Officer
• Robert Paul Eno,
  President
• Branislav Vajdic,
  CHIEF EXECUTIVE OFFICER